Metformin Prostate Cancer Adjuvant Trial

Brief description of study

The purpose of the study is to determine the safety and effectiveness of Metformin can increase Prostate Specific Antigen (PSA) doubling time for patients with Prostate Cancer who have failed primary treatment with radiation, or surgical patients who are at high risk for recurrence based on surgical pathology. We want to know if the treatment will reduce signs and symptoms of the disease. Metformin is an FDA-approved drug that is prescribed to treat high blood sugar levels in patients with Type 2 Diabetes.


Clinical Study Identifier: s18-01662
ClinicalTrials.gov Identifier: NCT02176161
Principal Investigator: Aaron Edward Katz.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.